Data Insights

Debio-0123 by Debiopharm International for Endometrial Cancer: Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Endometrial Cancer

Data Insights

Debio-0123 by Debiopharm International for Epithelial Ovarian Cancer: Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Epithelial Ovarian Cancer

Data Insights

Debio-0123 by Debiopharm International for Peritoneal Cancer: Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Peritoneal Cancer

Data Insights

Debio-0123 by Debiopharm International for Fallopian Tube Cancer: Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Fallopian Tube Cancer

Data Insights

Debio-0123 by Debiopharm International for Uterine Cancer: Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Uterine Cancer

Data Insights

Debio-0123 by Debiopharm International for Astrocytoma: Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase II for Astrocytoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-0123 in Astrocytoma

Data Insights

Debio-0123 by Debiopharm International for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Debio-0123 is under clinical development by Debiopharm International and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...

Data Insights

Alisporivir by Debiopharm International for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

Alisporivir is under clinical development by Debiopharm International and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...

Data Insights

Naratuximab emtansine by Debiopharm International for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma

Data Insights

Naratuximab emtansine by Debiopharm International for Mantle Cell Lymphoma: Likelihood of Approval

Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Mantle Cell Lymphoma

Data Insights

Naratuximab emtansine by Debiopharm International for Follicular Lymphoma: Likelihood of Approval

Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Follicular Lymphoma

Data Insights

Naratuximab emtansine by Debiopharm International for Non-Hodgkin Lymphoma: Likelihood of Approval

Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Non-Hodgkin Lymphoma

Data Insights

Naratuximab emtansine by Debiopharm International for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Naratuximab emtansine is under clinical development by Debiopharm International and currently in Phase II for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Marginal Zone B-cell Lymphoma

Data Insights

Octreotide ER by Debiopharm International for Acromegaly: Likelihood of Approval

Octreotide ER is under clinical development by Debiopharm International and currently in Phase II for Acromegaly. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Octreotide ER in Acromegaly

Data Insights

Debio-4228 by Debiopharm International for Metastatic Prostate Cancer: Likelihood of Approval

Debio-4228 is under clinical development by Debiopharm International and currently in Phase II for Metastatic Prostate Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-4228 in Metastatic Prostate Cancer

Data Insights

Debio-4326 by Debiopharm International for Central Precocious Puberty: Likelihood of Approval

Debio-4326 is under clinical development by Debiopharm International and currently in Phase III for Central Precocious Puberty. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Debio-4326 in Central Precocious Puberty

Data Insights

Afabicin by Debiopharm International for Osteomyelitis: Likelihood of Approval

Afabicin is under clinical development by Debiopharm International and currently in Phase II for Osteomyelitis. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Afabicin in Osteomyelitis